专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

41. 发明申请

WO2011053465A1 ANTIBODIES TO EPHA3 审中-公开
标题翻译：抗体EPHA3
公开(公告)号：WO2011053465A1
公开(公告)日：2011-05-05
申请号：PCT/US2010/052725
申请日：2010-10-14
申请人： KALOBIOS PHARMACEUTICALS, INC. , LUEHRSEN, Kenneth , MARTINEZ, David , YI, Christina , BEBBINGTON, Christopher R. , YARRANTON, Geoffrey T.
发明人： LUEHRSEN, Kenneth , MARTINEZ, David , YI, Christina , BEBBINGTON, Christopher R. , YARRANTON, Geoffrey T.
IPC分类号： C07K16/28 , C07K16/46
CPC分类号： C07K16/28 , C07K16/2866 , C07K2317/24 , C07K2317/41 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/72 , C07K2317/73 , C07K2317/92
摘要： The current disclosure relates to high-affinity antibodies to EphA3 that have reduced immunogenicity when administered to a human to treat diseases and method of using such antibodies.
摘要翻译：本公开涉及当向人类施用以治疗疾病时使免疫原性降低的EphA3的高亲和力抗体和使用该抗体的方法。

42. 发明申请

WO2010093814A1 METHODS OF TREATING DEMENTIA USING A GM-CSF ANTAGONIST 审中-公开
标题翻译：使用GM-CSF拮抗剂治疗DEMENTIA的方法
公开(公告)号：WO2010093814A1
公开(公告)日：2010-08-19
申请号：PCT/US2010/023931
申请日：2010-02-11
申请人： KALOBIOS PHARMACEUTICALS, INC. , BEBBINGTON, Christopher, R. , YARRANTON, Geoffrey, T. , PALATH, Varghese
发明人： BEBBINGTON, Christopher, R. , YARRANTON, Geoffrey, T. , PALATH, Varghese
IPC分类号： A61K38/19 , C07K14/535 , C07K16/28 , C07K16/24
CPC分类号： C07K16/243 , A61K31/13 , A61K31/445 , A61K38/1793 , A61K45/06 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/73 , C07K2317/76 , C07K2317/92 , A61K2300/00
摘要： The invention is based on the discovery that GM-CSF antagonists can be used for the treatment of a patient that has Alzheimer's disease or vascular dementia, or is at risk for developing Alzheimer's disease. Accordingly, the invention provides methods of administering a GM-CSF antagonist, e.g ., a GM-CSF antibody and pharmaceutical compositions comprising such antagonists.
摘要翻译：本发明基于以下发现：GM-CSF拮抗剂可用于治疗患有阿尔茨海默氏病或血管性痴呆的患者，或患有发展为阿尔茨海默氏病的风险。因此，本发明提供了施用GM-CSF拮抗剂，例如GM-CSF抗体和包含这种拮抗剂的药物组合物的方法。

43. 发明申请

WO2005069970A3 ANTIBODY SPECIFICITY TRANSFER USING MINIMAL ESSENTIAL BINDING DETERMINANTS 审中-公开
标题翻译：使用最小限度绑定决定因素的抗体特异性转移
公开(公告)号：WO2005069970A3
公开(公告)日：2009-03-12
申请号：PCT/US2005002072
申请日：2005-01-20
申请人： KALOBIOS INC , FLYNN PETER , LUEHRSEN KENNETH , BALINT ROBERT F , HER JENG-HORNG , BEBBINGTON CHRISTOPHER R , YARRANTON GEOFFREY T
发明人： FLYNN PETER , LUEHRSEN KENNETH , BALINT ROBERT F , HER JENG-HORNG , BEBBINGTON CHRISTOPHER R , YARRANTON GEOFFREY T
IPC分类号： G01N33/53 , C07K16/00 , C07K16/12 , C07K16/44 , C12N5/06 , C12N15/09 , C12P21/06 , C12Q1/70
CPC分类号： C07K16/00 , A61K2039/505 , C07K16/1214 , C07K2317/21 , C07K2317/24 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/92
摘要： The present invention provides methods of making antibodies having the binding specificity of a reference antibody. Antibodies generated by the methods of the inventions have at least one minimal essential binding specificity determinant from a heavy chain or light chain CDR3 from the reference antibody. The method can be used, e.g., in humanization procedures. The invention also provides libraries and antibodies made in accordance with the methods.
摘要翻译：本发明提供了制备具有参考抗体结合特异性的抗体的方法。通过本发明的方法产生的抗体具有来自参照抗体的重链CDR1或轻链CDR3的至少一种最小的必需结合特异性决定簇。该方法可以用于例如人源化程序中。本发明还提供了根据该方法制备的文库和抗体。

44. 发明申请

WO2008112192A2 EPHA3 ANTIBODIES FOR THE TREATMENT OF SOLID TUMORS 审中-公开
标题翻译：用于治疗实体瘤的EPHA3抗体
公开(公告)号：WO2008112192A2
公开(公告)日：2008-09-18
申请号：PCT/US2008003149
申请日：2008-03-10
申请人： KALOBIOS PHARMACEUTICALS INC , LACKMANN MARTIN , SCOTT ANDREW MARK , BEBBINGTON CHRISTOPHER R , YARRANTON GEOFFREY T
发明人： LACKMANN MARTIN , SCOTT ANDREW MARK , BEBBINGTON CHRISTOPHER R , YARRANTON GEOFFREY T
IPC分类号： A61K39/395 , A61P35/00
CPC分类号： C07K16/2866 , A61K47/6803 , A61K47/6849 , A61K51/1033 , A61K2039/505 , C07K2317/24 , C07K2317/73
摘要： The invention provides methods and compositions comprising anti-EphA3 antibodies for the treatment of solid tumors.
摘要翻译：本发明提供了用于治疗实体瘤的包含抗EphA3抗体的方法和组合物。

45. 发明申请

WO2005069970A2 ANTIBODY SPECIFICITY TRANSFER USING MINIMAL ESSENTIAL BINDING DETERMINANTS 审中-公开
标题翻译：使用最小限度绑定决定因素的抗体特异性转移
公开(公告)号：WO2005069970A2
公开(公告)日：2005-08-04
申请号：PCT/US2005/002072
申请日：2005-01-20
申请人： KALOBIOS, INC. , FLYNN, Peter , LUEHRSEN, Kenneth , BALINT, Robert, F. , HER, Jeng-Horng , BEBBINGTON, Christopher, R. , YARRANTON, Geoffrey, T.
发明人： FLYNN, Peter , LUEHRSEN, Kenneth , BALINT, Robert, F. , HER, Jeng-Horng , BEBBINGTON, Christopher, R. , YARRANTON, Geoffrey, T.
IPC分类号： C07K16/00 , C07K16/12 , C07K16/44 , C12N5/06 , C12N15/09 , C12P21/06
CPC分类号： C07K16/00 , A61K2039/505 , C07K16/1214 , C07K2317/21 , C07K2317/24 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/92
摘要： The present invention provides methods of making antibodies having the binding specificity of a reference antibody. Antibodies generated by the methods of the inventions have at least one minimal essential binding specificity determinant from a heavy chain or light chain CDR3 from the reference antibody. The method can be used, e.g., in humanization procedures. The invention also provides libraries and antibodies made in accordance with the methods.
摘要翻译：本发明提供了制备具有参考抗体结合特异性的抗体的方法。通过本发明的方法产生的抗体具有来自参照抗体的重链CDR1或轻链CDR3的至少一种最小的必需结合特异性决定簇。该方法可以用于例如人源化程序。本发明还提供了根据该方法制备的文库和抗体。

46. 发明申请

WO2002096910A1 CYTOTOXINS, PRODRUGS, LINKERS AND STABILIZERS USEFUL THEREFOR 审中-公开
标题翻译： CYTOTOXINS，PRODRUGS，LINKERS和STABILIZERS有用的
公开(公告)号：WO2002096910A1
公开(公告)日：2002-12-05
申请号：PCT/US2002/017210
申请日：2002-05-31
申请人： COULTER PHARMACEUTICAL, INC., A WHOLLY OWNED SUBSIDIARY OF CORIXA CORPORATION , NG, Howard, P. , MCGEE, Danny, P., C. , WU, Guoxian , LI, Zhihong , GANGWAR, Sanjeev , SAUNDERS, Oliver, L. , MARTICHONOK, Valeri , ASTAFIEVA, Irina , MOORE, Jimmie , YARRANTON, Geoffrey, Thomas , KING, David, J. , BOYD, Sharon , LOBL, Thomas, J.
发明人： NG, Howard, P. , MCGEE, Danny, P., C. , WU, Guoxian , LI, Zhihong , GANGWAR, Sanjeev , SAUNDERS, Oliver, L. , MARTICHONOK, Valeri , ASTAFIEVA, Irina , MOORE, Jimmie , YARRANTON, Geoffrey, Thomas , KING, David, J. , BOYD, Sharon , LOBL, Thomas, J.
IPC分类号： C07D487/04
CPC分类号： C07D405/06 , C07D231/12 , C07D233/56 , C07D249/08 , C07D405/12 , C07D405/14 , C07D487/04 , C07D487/10 , C07F7/1856 , C07F9/6561
摘要： The present invention provides analogues of duocarmycins that are potent cytotoxins. Also provided are peptidyl and disulfide linkers that are cleaved in vivo. The linkers are of use in forming prodrugs and conjugates of the cytotoxins of the invention as well as other diagnostic and therapeutic moieties. The invention provides prodrugs and conjugates of the duocarmycin analogues with the linker arms of the invention.
摘要翻译：本发明提供了作为有效的细胞毒素的杜卡霉素的类似物。还提供了在体内被切割的肽基和二硫键接头。连接体可用于形成本发明的细胞毒素的前药和缀合物以及其它诊断和治疗部分。本发明提供了杜卡霉素类似物与本发明的连接臂的前药和缀合物。

47. 发明申请

WO1991019739A1 MULTIVALENT ANTIGEN-BINDING PROTEINS 审中-公开
标题翻译：多功能抗体结合蛋白
公开(公告)号：WO1991019739A1
公开(公告)日：1991-12-26
申请号：PCT/GB1991000935
申请日：1991-06-11
申请人： CELLTECH LIMITED , KING, David, John , MOUNTAIN, Andrew , OWENS, Raymond, John , YARRANTON, Geoffrey, Thomas
发明人： CELLTECH LIMITED
IPC分类号： C07K13/00
CPC分类号： C07K16/18 , A01K2217/075 , A61K38/00 , A61K2039/505 , C07K16/00 , C07K16/468 , C07K2317/55 , C07K2317/622 , C07K2319/00
摘要： A multivalent antigen-binding protein comprises a first Fv fragment bound to at least one further Fv fragment by a connecting structure which links the Fv fragments to each other but which maintains them spaced apart such that the protein is capable of binding to adjacent antigenic determinants. Typically the connecting structure comprises a spacing polypeptide sequence, which may be about 3 to 16 amino acids in length, connected to a linkage unit which may be a synthetic chemical linker, e.g. a maleimide linker, or is a polypeptide sequence leading from the spacing sequence. In a particularly preferred embodiment the multivalent antigen binding protein comprises a VH domain having attached to its C-terminal end a V-C joining sequence and an antibody hinge sequence. Preferably one or more of the Fv fragments is a single chain Fv (scFv). The proteins are preferably prepared by recombinant DNA techniques and are useful for in vivo therapeutic and especially diagnostic applications.
摘要翻译：多价抗原结合蛋白包含通过连接结构与至少一个另外的Fv片段结合的第一Fv片段，其将Fv片段彼此连接，但是保持它们间隔开，使得蛋白质能够结合相邻的抗原决定簇。通常，连接结构包含间隔多肽序列，其可以是长度为约3至16个氨基酸，连接到可以是合成化学接头的连接单元，例如，马来酰亚胺接头，或是从间隔序列引出的多肽序列。在一个特别优选的实施方案中，多价抗原结合蛋白包含与其C末端连接V-C连接序列和抗体铰链序列的VH结构域。优选地，一个或多个Fv片段是单链Fv（scFv）。蛋白质优选通过重组DNA技术制备并且可用于体内治疗和特别是诊断应用。

48. 发明申请

WO1989002465A2 POLYPEPTIDE PRODUCTION 审中-公开
标题翻译：多肽生产
公开(公告)号：WO1989002465A2
公开(公告)日：1989-03-23
申请号：PCT/GB1988000747
申请日：1988-09-09
申请人： CELLTECH LIMITED , FIELD, Helen , REES, Anthony, Robert , YARRANTON, Geoffrey, Thomas
发明人： CELLTECH LIMITED
IPC分类号： C12N15/00
CPC分类号： C12N15/70 , A61K38/00 , C07K16/3015
摘要： A process for the production of a polypeptide comprising direct expression of the polypeptide in bacterial host cells characterised in that an inducible expression system is used in combination with a protease deficient bacterial host system. The process is particularly useful for the production of small polypeptides especially immunologically functional antibody fragments and in particular heavy and light chain polypeptides comprising complementary variable domains. Further aspects of the invention relate to suitable expression vectors and bacterial host systems.
摘要翻译：一种生产多肽的方法，包括在细菌宿主细胞中直接表达多肽，其特征在于诱导型表达系统与蛋白酶缺陷型细菌宿主系统组合使用。该方法特别可用于生产小多肽，特别是免疫功能性抗体片段，特别是包含互补可变结构域的重链和轻链多肽。本发明的其它方面涉及合适的表达载体和细菌宿主系统。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式